quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Webull aims to double premium subscribers and expand B2B platform in 2026 as AI drives platform growth

View original at seekingalpha.com
Webull aims to double premium subscribers and expand B2B platform in 2026 as AI drives platform growth Earnings Call Insights: Webull Corporation (BULL) Q4 2025 MANAGEMENT VIEW * Anthony Michael Denier, President & Director, highlighted "strong progress and returns for our first full year as a public company," emphasiz…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Webull will continue to be very focused on investing in growth, primarily in organic growth as we see a lot of opportunities in our current space

    80% confidence

  • Prediction markets are not going to be any part of Webull's core business going forward

    80% confidence

  • Customer assets reached $24.6 billion, an 81% increase from 2024

    80% confidence

  • Webull Premium has reached 102,000 subscribers by year-end, surpassing the 100,000 target

    80% confidence

  • January 2026 is probably the second best month in company history since inception, and Q1 2026 is certainly looking strong

    80% confidence

  • Webull recorded revenue of $571 million in 2025, representing 46% growth from 2024, driven by record trading volumes across all asset categories

    80% confidence

  • Non-U.S. broker-dealers have more than doubled the amount of incoming flow over the course of 2025

    80% confidence

  • Webull has more than 760,000 funded accounts outside the U.S.

    80% confidence

  • Webull is poised to bring solutions to brokerage firms, high-net-worth individuals, family offices and wealth advisers through B2B platform expansion

    80% confidence

  • B2B relationships are not attributable to net deposits; those net deposits are purely coming from retail, though crypto is included because crypto business is only attributed to retail

    80% confidence

  • Webull expects to bring digital asset licenses online in multiple new markets in the coming year (2026)

    80% confidence

  • Vega currently assists 1.2 million global users each week with 10% of weekly active users deploying the tool to answer over 10 million questions since creation

    80% confidence

  • In Q4 2025, Webull generated total revenue of $165.2 million, representing 50% year-over-year growth, reflecting continued strength across both trading and interest-related income streams

    80% confidence

  • Q4 marketing expense was higher and primarily focused on acquiring high-net-worth active trading customers, but Q1 marketing costs are expected to be much lighter than Q4

    80% confidence

  • Webull aims to double premium subscriber base in the coming year (2026) while continuing to enhance the product with additional features

    80% confidence

  • Webull will continue to invest in customer acquisition and AUM growth while keeping an eye on marketing spend as a percentage of revenue

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Webull aims to double premium subscribers and expand B2B platform in 2026 as AI drives platform growth — Source | Via News | pt.VIA.NEWS